Please wait

Спасибо.
В теченее 15 минут c Вами свяжеться наш специалист.

НАВЕДИ ПОРЯДОК
В СВОЕЙ ТОРГОВЛЕ

Бесплатное PDF-руководство с 11 инструментами,
используя которые Вы в разы повысите качество торговли на финансовых рынках.

Не хочу зарабатывать больше

Reducing of Bristol-Myers Squibb`s development prospects

assets
08 June 2017 , 13:20

The share price of an American pharmaceutical company Bristol-Myers Squibb (ticker: BMY) have been in a steady downtrend since the beginning of this year. The main reason of this situation is the absence of obvious advantages and results of the Opdivo product, which is aimed at fighting cancer.

Fundamental factors

The biggest share of company`s revenue take sales of Opdivo drug. However, at the last conference of biopharmaceutical companies, the head of BMY announced that he had started working with Novartis to study the safety, tolerability and effectiveness of Opdivo. This information gives reasons to believe the market that the company doesn`t give 100% confidence in combat with the disease using this drug.

Fig.1. Sales of Bristol-Myers Squibb products

In order to further explore the analysis, as well as the entry point to the position, you can see full details in the personal account of our TSI Trading Pro platform.

Уникальный курс обучения

Алготрейдингу

Ваш собственный торговый робот

за 30 дней

Получить первый урок

совершенно бесплатно

TSI RECOMMENDS
TSI community
Sign up to our newsletter

Sign up for our newletter and do not miss any important news
of world of finance!

You can always unsubscribe if you do not like

facebook

Нажмите «Нравится», чтобы читать TSI Analitycs в Facebook
X

Уникальный курс обучения

Алготрейдингу

Ваш собственный торговый робот

за 30 дней

Получить первый урок

совершенно бесплатно

Sign up to our newsletter

Sign up for our newletter and do not miss any important news of world of finance!

You can always unsubscribe if you do not like